Active lawsuitDangerous drugsMDL No. 3094 and No. 3163
GLP-1 medication lawsuits
Ozempic, Wegovy, Rybelsus, Trulicity and Mounjaro are prescribed to millions of people for type 2 diabetes and weight management. Lawsuits now pending in federal court allege that these medicines can cause serious stomach and bowel injuries, and a rare optic nerve condition, and that the makers did not adequately warn patients or doctors. Our legal team reviews these cases. If you used one of these medicines and were diagnosed with one of the conditions below, you can ask for a free case evaluation.
the pharmacy label has the dates
This page summarizes what pending lawsuits allege, based on court records and official sources. Allegations in a lawsuit are not findings by a court. It's general information, not legal advice about your situation. Last reviewed October 12, 2026.
On this page
Safety note: Don't stop or change a prescribed medicine without talking to your doctor.
At a glance
GLP-1 Medication Lawsuits (Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro)
- Litigation
- In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094; and the related NAION litigation, MDL No. 3163
- Court
- U.S. District Court for the Eastern District of Pennsylvania
- Judge
- Judge Karen S. Marston (both MDLs)
- Centralized
- February 2, 2024 (MDL No. 3094); December 15, 2025 (MDL No. 3163)
- Products named
- Ozempic, Wegovy and Rybelsus (semaglutide, Novo Nordisk); Trulicity (dulaglutide) and Mounjaro (tirzepatide) (Eli Lilly and Company)
What the lawsuits allege
- Gastrointestinal injuries (MDL No. 3094). Plaintiffs allege that GLP-1 receptor agonist medicines can cause gastroparesis, a condition in which the stomach empties too slowly, along with ileus, intestinal obstruction or pseudo-obstruction, and other gastrointestinal injuries.
- NAION (MDL No. 3163). Plaintiffs allege that these medicines can cause non-arteritic anterior ischemic optic neuropathy (NAION), a condition in which blood flow to the optic nerve is reduced, which can cause sudden vision loss.
- Warnings. The lawsuits allege the makers knew or should have known about these risks and did not adequately warn patients or their prescribing doctors.
Novo Nordisk and Eli Lilly and Company deny these allegations. An MDL means many people have filed similar lawsuits. It does not mean any court has decided that these medicines caused anyone's injury.
Who may be eligible
You may be eligible for a free case evaluation if you used Ozempic, Wegovy, Rybelsus, Trulicity or Mounjaro and were diagnosed with gastroparesis, ileus, an intestinal obstruction or another serious gastrointestinal injury, or with NAION, an optic nerve condition that can cause vision loss.
Our attorneys look at
- Which medicine you used, and when you started and stopped
- What you were diagnosed with, and when
- How the diagnosis was made and what treatment you needed, such as an emergency visit, a hospital stay or surgery
What to gather for your free evaluation
You don't need everything on this list to ask for an evaluation. Gather what you can.
- Pharmacy or prescription records showing the medicine, dose and dates
- The names of the doctors who prescribed it and who treated your injury
- Medical records for the diagnosis, including test results such as a gastric emptying study or imaging, if you had them
- Emergency room, hospital and surgery records
- For vision problems: eye exam and ophthalmology records
- A short timeline of your symptoms and treatment
- Records of missed work or other effects on your daily life
Where the litigation stands
As of October 2026
- LitigationMDL No. 3094 (gastrointestinal injuries) and MDL No. 3163 (NAION eye condition)
- CourtU.S. District Court for the Eastern District of Pennsylvania
- JudgeJudge Karen S. Marston (both MDLs)
- CreatedMDL No. 3094: February 2, 2024. MDL No. 3163: December 15, 2025.
As of October 2026, lawsuits allege that GLP-1 receptor agonist medicines can cause gastroparesis and other gastrointestinal injuries (MDL No. 3094) and the eye condition NAION (MDL No. 3163), and that the makers did not adequately warn about these risks. Both MDLs are pending before Judge Karen S. Marston in the Eastern District of Pennsylvania. From September 14 to 18, 2026, Judge Marston held a Rule 702 evidentiary hearing on expert evidence for issues common to many of the gastrointestinal cases. The JPML created the separate NAION MDL in December 2025 and assigned it to the same judge.
What regulators have said
The FDA-approved prescribing information for these medicines, available on DailyMed, describes gastrointestinal adverse reactions. On June 6, 2025, the European Medicines Agency announced that its safety committee had concluded NAION is a very rare side effect of the semaglutide medicines Ozempic, Rybelsus and Wegovy, and recommended adding it to the European product information.
Status checked October 12, 2026. Both MDLs are listed as pending on the JPML report of pending MDLs dated October 1, 2026 (opens in a new tab). Court dockets change; each page shows the date it was last checked.
Questions
I still take one of these medicines. Should I stop?
Not without talking to your doctor. These medicines treat serious conditions, and stopping or changing a dose on your own can be harmful. A case evaluation doesn't require you to change your treatment.
Is this a class action?
No. In an MDL, each person keeps an individual lawsuit. The cases are grouped before one federal judge for pretrial work such as evidence exchange and rulings on expert testimony.
Is there a deadline?
Yes. Each state sets its own filing deadline, called a statute of limitations, and an MDL does not pause it. The deadline that applies to you depends on your state and the facts of your case, so it's best to ask early.
What happens after I ask for an evaluation?
Our legal team reviews what you tell us, and we will contact you to talk about your situation and any records we may need.
Official sources
Each link opens the original record in a new tab.
- U.S. District Court, Eastern District of PennsylvaniaU.S. District Court, E.D. Pa.: MDL 3094 In re GLP-1 RAs Products Liability Litigationpaed.uscourts.gov (opens in a new tab)
- Judicial Panel on Multidistrict LitigationJPML Transfer Order, MDL No. 3094 (filed Feb. 2, 2024)jpml.uscourts.gov (opens in a new tab)
- Judicial Panel on Multidistrict LitigationJPML Transfer Order, MDL No. 3163 (filed Dec. 15, 2025)jpml.uscourts.gov (opens in a new tab)
- European Medicines AgencyEuropean Medicines Agency: PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines (June 6, 2025)ema.europa.eu (opens in a new tab)
- National Library of Medicine, DailyMedDailyMed: current prescribing information (search: Ozempic)dailymed.nlm.nih.gov (opens in a new tab)
- Judicial Panel on Multidistrict LitigationJPML: Pending MDL Dockets by MDL Type, report date October 1, 2026jpml.uscourts.gov (opens in a new tab)
Used a GLP-1 medicine and were diagnosed with one of these conditions?
Tell us what happened in a few sentences. Our legal team reviews every request, and we will contact you about your free case evaluation.
a few sentences is enough
A free case evaluation does not create an attorney-client relationship, does not file a claim and does not pause any deadline. We represent a client only after we both sign a written agreement.
a few sentences is enough